Castle Biosciences Announces Publication of Study Demonstrating the Integration of DecisionDx®-Melanoma and Clinicopathologic Factors Provides Optimized, Personalized Survival Prognoses for Patients with Cutaneous Melanoma
DecisionDx-Melanoma integrates a patient’s clinicopathologic factors with his/her tumor biology to provide precise, personalized risk estimates, including five-year melanoma-specific survival, recurrence-free survival and distant metastasis-free survival FRIENDSWOOD, Texas–(BUSINESS WIRE)–$CSTL #CSTL–Castle Biosciences, Inc. (Nasdaq: CSTL), a company improving health through innovative tests that guide patient care, today announced the publication of a study in the Journal … [Read more…]
